http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 31 Mar 2026 03:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled <i>"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial"</i> in the esteemed peer reviewed journal Frontiers in veterinary science (<a target="_blank" href="https://doi.org/10.3389/fvets.2025.1746266" target="_blank" rel="nofollow">https://doi.org/10.3389/fvets.2025.1746266</a>) ⁽¹⁾.</p> <div id="prni_dvprnejpg9172left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg9172left" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Key findings http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Announces+LPT-CBD+demonstrates+Pain+Relief+over+Placebo-Results+from+a+randomized+blinded+clinical+study+in+Dogs/25965801.html Mon, 09 Feb 2026 09:07:00 -0400 A.41307835 INNO INNPD INNPF IP4 IP4 IP4 IP4 IP4 IP4 IP40 IP40 IP40 IP40 IP40 IP40 O.01239210 O.46550843